Rexahn Pharmaceuticals Inc.
Home
About
Partnering
Portfolio
Discovery Platform
Investor Relations
Media Center
Contact
CONTACTS:
Stephanie Ascher
Stern Investor Relations, Inc.
212-362-1200
stephanie@sternir.com
Constantine Theodoropulos
Base Pair Communications
617-401-3116
constantine@basepaircomm.com
About
A powerful discovery engine and differentiated product pipeline and the expertise to develop cures for the major diseases of our time.
News
Rexahn Pharmaceuticals Submits Serdaxin Phase IIb Protocol to FDA for Major Depressive Disorder (MDD)
September 7th, 2010
Rexahn Pharmaceuticals Announces Publication of New Preclinical Research Data for Novel Anticancer Compound RX-8243
September 4th, 2010
Portfolio
* Serdaxin Q&A
* Zoraxel Q&A